Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
NCT07006675
Recruiting
Two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial evaluating the efficacy of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2025
Locations: Eskenazi Hospital, Indianapolis, Indiana +13 locations
Conditions: Tibial Fractures, Pain
Register for Updates
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
NCT04802707
Recruiting
Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are a genetically and clinically heterogeneous group of autosomal recessive disorders that are characterized by a severe reduction in mtDNA content leading to impaired energy production in affected tissues and organs. MDS are due to defects in mtDNA maintenance caused by mutations in nuclear genes that function in either mitochondrial nucleotide synthesis. MDS are phenotypically heterogeneous and usually classified as myopathic, encephalomyopat... Read More
Gender:
ALL
Ages:
Between 1 month and 60 years
Trial Updated:
05/27/2025
Locations: Research InstituMcGill University Health Centre - Children Hospital of Montreal, Montréal, Quebec
Conditions: Mitochondrial Diseases, Mitochondrial Encephalomyopathy, Mitochondrial Encephalopathy, Mitochondrial DNA Depletion, Mitochondrial Metabolism Disorders
Register for Updates
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
05/27/2025
Locations: Cenexel, Englewood, Colorado +38 locations
Conditions: Huntington's Disease
Register for Updates
CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
NCT06700304
Recruiting
The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, which is a machine designed to carefully place these threads. This study will help researchers learn how well the implant and robot work and if they are safe for use.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/27/2025
Locations: University Health Network, Toronto, Ontario
Conditions: Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Injury (Quadraplegia), Spinal Cord Injury
Register for Updates
Multi-Center PAMPA Study
NCT05004727
Recruiting
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an interventi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +4 locations
Conditions: Psoriasis
Register for Updates
Fetal Ebstein Anomaly and Tricuspid Valve Dysplasia Registry
NCT05225311
Recruiting
Ebstein anomaly and tricuspid valve dysplasia (EA/TVD) are rare congenital tricuspid valve malformations that carry among the highest mortality of all congenital heart disease diagnosed in utero. Despite the high mortality associated with severe EA/TVD in the fetus, it has only been studied retrospectively. By prospectively enrolling a cohort across multiple centers, many questions may be answered in the perinatal period and beyond. The registry will allow us to understand perinatal and postnata... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/27/2025
Locations: The Hospital for Sick Children, Toronto, Ontario
Conditions: Ebstein Anomaly, Tricuspid Valve Dysplasia
Register for Updates
Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]
NCT06216470
Recruiting
This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection. The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body. This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of app... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/27/2025
Locations: University Health Network, Toronto, Ontario
Conditions: Hepatitis B, Chronic
Register for Updates
A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm
NCT06991517
Recruiting
The goal of this study is to learn what effects the ABC Bicuspid Sizing Algorithm has on the clinical outcomes of patients with bicuspid aortic stenosis after having a transcatheter aortic valve replacement (TAVR) using the Sapien 3 valve. The main questions the study aims to answer are: 1. Does the ABC Bicuspid Sizing Algorithm increase the technical success at exit from the procedure room? 2. Does the ABC Bicuspid Sizing Algorithm increase the device success at 30 days after the procedure? P... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/26/2025
Locations: John Hunter Hospital, New Lambton Heights, New South Wales +19 locations
Conditions: Aortic Stenosis
Register for Updates
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
NCT06603870
Recruiting
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: The Ottawa Hospital, Ottawa, Ontario
Conditions: Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
Register for Updates
Investigating the Efficacy of an Augmented Virtual Reality Driving Simulator on Institutionalized Dementia Patients
NCT06419257
Recruiting
The improvement in health and welfare in modern society has led to an increase in life expectancy. Alternatively, the longer one lives, the more likely to experience deterioration in memory, cognitive ability, and executive function skills in our brains. While some cognitive impairments can be typical results of normal aging, a decline in spatial cognition can be a sign of dementia, especially Alzheimer's disease (AD). Based on the neuroplasticity of the brain even at old ages, there are some ho... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/26/2025
Locations: Riverview Health Center, Winnipeg, Manitoba
Conditions: Advance Dementia
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: University of Arkansas, Little Rock, Arkansas +108 locations
Conditions: Multiple Myeloma
Register for Updates
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
NCT06416085
Recruiting
The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone, Stage IV Lymphoma, Stage IV Melanoma, Endocrine Cancer
Register for Updates